age-related macular degeneration

News
EyeBio

Update: MSD confirms $3bn takeover of EyeBio

MSD has confirmed a $3 billion takeover deal for ophthalmology biotech EyeBio and its drug candidate for diabetic macular oedema (DME) and neovascular age-related macular